New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer

• Published in: European urology focus 2024-07, Vol.10 (4), p.514-517
• Main Authors: Hébert, Kévin, Bodin-Cufi, Paul, Fersing, Cyril, Deshayes, Emmanuel
• Format: Article
• Language: English
• Subjects: Dipeptides - therapeutic use; Heterocyclic Compounds, 1-Ring - therapeutic use; Humans; Lutetium - therapeutic use; Male; Metastatic prostate cancer; Molecular Targeted Therapy - methods; Neoplasm Metastasis; Prostate-specific membrane antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radioisotopes - therapeutic use; Radiopharmaceuticals - therapeutic use; Targeted radionuclide therapy
• ISSN: 2405-4569; 2405-4569
• DOI: 10.1016/j.euf.2024.07.016

Targeted radionuclide therapy has become a readily available option for metastatic prostate cancer since the approval of [177Lu]Lu-PSMA-617. Various novel radiopharmaceuticals are currently being investigated for treatment in this setting. Promising innovations include chemical modifications to improve pharmacokinetics, identification of new targets, and the use of novel radioisotopes such as α emitters. Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.